etesevimab

^[1]^[2]^[3]

Indications

treatment of outpatients with COVID-19 >= 14 years of age >= 40 kg
- especially adults >= 65 years with COVID-19 at risk for severe disease

* must be administered in combination with bamlanivimab

not authorized in hospitalized patients or patients who require oxygen therapy for COVID-19
bamlanivimab + etesevimab not effective against Omicron^[3] (off market Jan 2022)

* may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation

↑ Gottlieb RL, Nirula A, Chen P et al Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19A Randomized Clinical Trial. JAMA. Published online January 21, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33475701 https://jamanetwork.com/journals/jama/fullarticle/2775647
Malani PN, Golub RM. Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19. JAMA. Published online January 21, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33475716 https://jamanetwork.com/journals/jama/fullarticle/2775645
↑ Walker M FDA OKs Antibody Combo for Milder COVID-19 - Cut hospitalizations, deaths in patients at high risk of severe disease. MedPage Today February 10, 2021 https://www.medpagetoday.com/infectiousdisease/covid19/91136
↑ ^3.0 ^3.1 American Medical Association (AMA) AMA Morning Rounds. Jan 25, 2022